Opinion

Video

Concluding Thoughts on Ph+ ALL Treatment

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.

In conclusion, Dr Abbas stressed engaging community practices more in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) care while ensuring specialist leadership and optimal up-front therapy access. Dr Jabbour highlighted immense survival gains from 10% to 90% in recent years, with cures becoming reality now—not just ideals for the future. Equity in access to best available treatments remains vital. Dr McCloskey advised rethinking outdated potent toxicity perceptions given new safety data enabling more appropriate patient selection. Robust measurable residual disease monitoring must inform Ph+ ALL management everywhere. Dr Ebot-Tar discussed payers balancing innovation support, value demonstration to stakeholders, and personalized care. Ongoing collaboration between specialties and health plans can continue progress.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
A panel of 4 experts on PDTs
A panel of 4 experts on PDTs
A panel of 5 experts on Alzheimer disease
A panel of 5 experts on Alzheimer disease
Video 2 - "SunRISe-1: Examining Combination Therapy for HR NMIBC"
Video 1 - "Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC "
Ravin Ratan, MD, MEd, MD Anderson
Dr Migvis Monduy
Paul Frohna, MD, PhD, PharmD.
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Related Content
CH LogoCenter for Biosimilars Logo